June 10, 2003Circulation
Randomized, Double-Blind, Placebo-Controlled, Pilot Trial of Infliximab, a Chimeric Monoclonal Antibody to Tumor Necrosis Factor-α, in Patients With Moderate-to-Severe Heart Failure
Why the study?
Does infliximab improve the clinical condition in patients with moderate-to-severe chronic heart failure?
Population
Patients with moderate-to-severe chronic heart failure
Comparison
Infliximab vs Placebo
Design
RCT, Randomized, Double-Blind
Follow-up
Short-term
Authors
Discussion
Loading...
Member takes
Implication
Avoid infliximab in moderate-to-severe HF due to lack of benefit and high-dose harm; challenges TNFα antagonism as a therapeutic target.
Structured PICO
Does infliximab improve the clinical condition in patients with moderate-to-severe chronic heart failure?
P
Population
Patients with moderate-to-severe chronic heart failure
I
Intervention
Infliximab (short-term TNFalpha antagonism, including high doses of 10 mg/kg)
C
Comparator
Placebo
O
Outcome
Clinical condition
Short-term use of infliximab does not benefit and may harm patients with moderate-to-severe heart failure, particularly at high doses.
Cite This Study
Chung et al. (2003) studied this question.